Clinical Significance of Combined Assessment of the Maximum Standardized Uptake Value of F-18 FDG PET with Nodal Size in the Diagnosis of Cervical Lymph Node Metastasis of Oral Squamous Cell Carcinoma

Academic Radiology

Volumn 19, Issue 6, 2012, Pages 708-717

  Matsubara, Ryota ^a   Kawano, Shintaro ^a   Chikui, Toru ^a   Kiyosue, Takahiro ^a   Goto, Yuichi ^a   Hirano, Mitsuhiro ^a   Jinno, Teppei ^a   Nagata, Tetsuji ^b   Oobu, Kazunari ^a   Abe, Koichiro ^c   Nakamura, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Cervical lymph node metastasis; Diagnosis; F 18 FDG PET; Maximum standardized uptake value (SUVmax); Nodal size; Oral squamous cell carcinoma (OSCC)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; B SCAN; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NECK DISSECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NECK; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84860601373     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2012.02.009     Document Type: Article

References (55)

1. Platz H., Fries R., Hudec M. Retrospective DOSAK study on carcinomas of the oral cavity: results and consequences. J Maxillofac Surg 1985, 13:147-153.
2. Snow G.B., Patel P., Leemans C.R., et al. Management of cervical lymph nodes in patients with head and neck cancer. Eur Arch Otorhinolaryngol 1992, 249:187-194.
3. Steinkamp H.J., Hosten N., Richter C., et al. Enlarged cervical lymph nodes at helical CT. Radiology 1994, 191:795-798.
4. Curtin H.D., Ishwaran H., Mancuso A.A., et al. Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998, 207:123-130.
5. Yuasa K., Kawazu T., Nagata T., et al. Computed tomography and ultrasonography of metastatic cervical lymph nodes in oral squamous cell carcinoma. Dentomaxillofacial Radiol 2000, 29:238-244.
6. Yuasa K., Kawazu T., Kunitake N., et al. Sonography for the detection of cervical lymph node metastases among patients with tongue cancer: criteria for early detection and assessment of follow-up examination intervals. Am J Neuroradiol 2000, 21:1127-1132.
7. Bar-Shalom R., Valdivia A.Y., Blaifox M.D. PET imaging in oncology. Semin Nucl Med 2000, 30:150-185.
8. 18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancer. Curr Opin Oncol 2005, 17:249-253.
9. 18F-fluorodeoxyglucose positron emission tomography in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 93:202-207.
10. Suzuki H., Hasegawa Y., Terada A., et al. FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma. Oral Oncol 2009, 45:569-573.
11. Krabbe C.A., Pruim J., Dijkstra P.U., et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med 2009, 50:1940-1947.
12. Senft A., de Bree R., Hoekstra O.S. Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. Radiother Oncol 2008, 87:221-229.
13. Miller F.R., Hussey D., Beeram M., et al. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg 2005, 131:626-629.
14. Goerres G.W., Schmid D.T., Grätz K.W., et al. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2003, 39:547-551.
15. Bruschini P., Giogetti A., Bruschini L., et al. Positron emission tomography (PET) in the staging of head neck cancer: comparison between PET and CT. Acta Otorhinolaryngol Ital 2003, 23:446-453.
16. Schwartz D.L., Rajendran J., Yueh B., et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004, 130:1361-1367.
17. 18F-FDG-PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 2005, 46:1136-1143.
18. 18FDG PET. Am J Roentgenol 2005, 184:1326-1331.
19. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006, 47:755-762.
20. Hafidh M.A., Lacy P.D., Hughes J.P., et al. Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas. Eur Arch Otorhinolaryngol 2006, 263:853-859.
21. 18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 2006, 24:4371-4376.
22. 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 2007, 48:752-757.
23. 18F-fluorodeoxyglucose positron emission tomography in the preoperative staging of squamous cell carcinoma of the oropharynx. Eur J Surg Oncol 2007, 33:633-638.
24. Murakami R., Uozumi H., Hirai T., et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007, 68:377-382.
25. Nahmias C., Carlson E.R., Duncan L.D., et al. Positron emission tomography/computed tomography (PET/CT) scanning for preoperative staging of patients with oral/head and neck cancer. J Oral Maxillofac Surg 2007, 65:2524-2535.
26. Gordin A., Golz A., Keidar Z., et al. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolarygol Head Neck Surg 2007, 137:130-137.
27. 18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol 2007, 43:887-893.
28. Murakami R., Uozumi H., Hirai T., et al. Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma: intermethod and interobserver variations. Acta Radiol 2008, 49:693-699.
29. Yamazaki Y., Saitoh M., Notani K., et al. Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med 2008, 22:177-184.
30. Kyzas P.A., Evangelou E., Denaxa-Kyza D., et al. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008, 100:712-720.
31. Krabbe C.A., Dijkstra P.U., Pruim J., et al. FDG PET in oral and oropharyngeal cancer. Value for confirmation of N0 neck and detection of occult metastases. Oral Oncol 2008, 44:31-36.
32. Goerres G.W., Schunknecht B., Schmid D.T., et al. Positron emission tomography/computed tomography for staging and restaging of head and neck cancer: comparison with positron emission tomography read together with contrast-enhanced computed tomography. Clin Imaging 2008, 32:431-437.
33. Kato H., Kimura H., Nakajima M., et al. The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer. Oncol Rep 2008, 20:857-862.
34. 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol 2009, 19:634-642.
35. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002, 2:683-693.
36. Vesselle H., Schmidt R.A., Pugsley J.M., et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000, 6:3837-3844.
37. Buck A., Schirrmeister H., Kühn T., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002, 29:1317-1323.
38. Machtay M., Natwa M., Andrel J., et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009, 31:195-201.
39. Ishikita T., Oriuchi N., Higuchi T., et al. Additional value of integrated PET/CT over PET alone in the initial staging and follow up of head and neck malignancy. Ann Nucl Med 2010, 24:77-82.
40. 18F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy. Oral Oncol 2006, 42:297-305.
41. 18F)fluorodeoxyglucose (FDG) in head and neck tumours. Acta Otolaryngol 2007, 127:186-193.
42. Liao C.T., Chang J.T., Wang H.M., et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009, 73:764-771.
43. Miyawaki A., Ikeda R., Hijioka H., et al. SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma. Oncol Rep 2010, 23:1205-1212.
44. Sobin L.H., Wittekind C.H. TNM classification of malignant tumors 2002, International Union against Cancer, John Wiley-Liss. 6th ed.
45. Metz C.E. ROC methodology in radiology imaging. Invest Radiol 1986, 21:720-733.
46. Ariji E., Nagata T., Miwa K., et al. Diagnostic analysis of cervical lymph nodes in patients with squamous cell carcinoma using CT and US. Oral Radiol 1991, 7:1-12.
47. Ishii J., Amagasa T., Tachibana T., et al. US and CT evaluation of cervical lymph node metastasis from oral cancer. J Craniomaxillofac Surg 1991, 19:123-127.
48. Yonetsu K., Sumi M., Izumi M., et al. Contribution of Doppler sonography blood flow information to the diagnosis of metastatic cervical nodes in patients with head and neck cancer: assessment in relation to anatomic levels of the neck. Am J Neuroradiol 2001, 22:163-169.
49. Chikui T., Yonetsu K., Nakamura T. Multivariate feature analysis of sonographic findings of metastatic cervical lymph nodes: contribution of blood flow features revealed by power Doppler sonography for predicting metastasis. Am J Neuroradiol 2000, 21:561-567.
50. Adams S., Baum R.P., Stuckensen T., et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MR imaging, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998, 25:1255-1260.
51. Stuckensen T., Kovacs A.F., Adams S., et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000, 28:319-324.
52. 18F-fluorodeoxyglicose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002, 236:208-217.
53. Crippa F., Leutner M., Belli F., et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000, 41:1491-1494.
54. Takamochi K., Yoshida J., Murakami K., et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung cancer 2005, 47:235-242.
55. Stoeckli S.J., Pfaltz M., Steinert H., et al. Histopathological features of occult metastasis detected by sentinel lymph node biopsy in oral and oropharyngeal squamous cell carcinoma. Laryngoscope 2002, 112:111-115.